F S&P 500
5,120.25 +38.00 (+0.75%) F Dow Jones
38,328.00 +40.00 (+0.10%) F Nasdaq
17,749.50 +182.00 (+1.04%) E-mini Russell 2000 Index Futur
1,993.20 0.00 (0.00%) Petróleo
84.17 +0.60 (+0.72%) Oro
2,358.50 +16.00 (+0.68%)
Collegium Pharmaceutical, Inc. (COLL)
Fuera de horario:
Collegium Pharmaceutical, Inc.
100 Technology Center Drive
Suite 300
Stoughton, MA 02072
United States
781 713 3699
https://www.collegiumpharma.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 197
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. | Co-Founder & Independent Chairman | 110k | N/D | 1964 |
| Mr. Joseph J. Ciaffoni | President, CEO & Director | 1.45M | 770.46k | 1971 |
| Ms. Colleen Tupper | Executive VP & CFO | 782.64k | N/D | 1976 |
| Ms. Shirley R. Kuhlmann | Executive VP, General Counsel, Chief Administrative Officer & Secretary | 788.45k | 252.97k | 1984 |
| Mr. Scott Dreyer | Executive VP & Chief Commercial Officer | 693.54k | N/D | 1972 |
| Dr. Thomas B. Smith FAAFP, M.D. | Executive VP & Chief Medical Officer | 693.27k | N/D | 1961 |
| Dr. Christopher Shayne James M.D. | Vice President of Investor Relations | N/D | N/D | N/D |
| Mr. Bart J. Dunn | Executive Vice President of Strategy & Corporate Development | N/D | N/D | N/D |
| Mr. Scott Sudduth | Head of Technical Operations | N/D | N/D | N/D |
Descripción
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Collegium Pharmaceutical, Inc. a partir del 1 de abril de 2024 es 3. Las puntuaciones principales son Auditoría: 9; Junta: 4; Derechos del accionista: 2; Compensación: 3.
